Literature DB >> 27878685

The Role of IL-33 on LPS-Induced Acute Lung Injury in Mice.

Yaping Zhang1, Ran Lv1, Xuming Hu1, Li Jiang1, Dongju Xiao1, Yv Sun1, Jinning Zhao1, Qi Bao1, Junran Xie2.   

Abstract

The objective of the study is to investigate the role and specific molecular mechanism of interleukin-33 (IL-33) acted on acute lung injury (ALI) induced by lipopolysaccharide (LPS). C57BL/6 mice intratracheally instilled LPS to induce ALI model. The mice were randomly divided into three groups: the sham operation group (Sham), ALI group (ALI), and pretreatment with IL-33 of ALI group (IL-33). By observing the survival rate, inflammatory cytokines in bronchoalveolar lavage fluid (BALF), myeloperoxidase (MPO) levels in lung tissue, lung histopathological examination, pulmonary capillary leakage, lung wet/dry (W/D) weight ratio, fibrosis levels in lung tissue, and associated pathways changes among the different groups, comparing to explore the role of IL-33 pretreatment on ALI mice and the possible molecular mechanisms. IL-33 pretreatment overall decreased the survival rate of ALI mice. IL-33 aggravated inflammation reaction showing as increasing the release of proinflammatory cytokines TNF-α and IL-6, increasing MPO levels in lung tissue, and aggravating lung pathology injury. In addition, IL-33 pretreatment further destroyed adherens junctions (AJs) by increasing the phosphorylation of VE-cadherin, resulting in the concomitantly pulmonary capillary barrier damage and pulmonary edema. During this process, mitogen-activated protein kinase (MAPK) pathways further activated. However, IL-33 pretreatment had no significant impact on collagen content of lung tissue. Our results indicated that IL-33 aggravated inflammatory reaction and increased microvascular permeability, but had little effect on pulmonary fibrosis, associated with the further activation of MAPK family proteins in the process. To sum up, IL-33 decreased survival rate and aggravated LPS-induced ALI.

Entities:  

Keywords:  ALI; IL-33; MAPK

Mesh:

Substances:

Year:  2017        PMID: 27878685     DOI: 10.1007/s10753-016-0479-z

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  33 in total

1.  IL-33 mediates inflammatory responses in human lung tissue cells.

Authors:  Akiko Yagami; Kanami Orihara; Hideaki Morita; Kyoko Futamura; Noriko Hashimoto; Kenji Matsumoto; Hirohisa Saito; Akio Matsuda
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection.

Authors:  Jose C Alves-Filho; Fabiane Sônego; Fabricio O Souto; Andressa Freitas; Waldiceu A Verri; Maria Auxiliadora-Martins; Anibal Basile-Filho; Andrew N McKenzie; Damo Xu; Fernando Q Cunha; Foo Y Liew
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

3.  Hydroxyethyl starch (130 kD) inhibits Toll-like receptor 4 signaling pathways in rat lungs challenged with lipopolysaccharide.

Authors:  Jie Tian; Yunxia Wang; Zhengyu He; Yuan Gao; Joyce E Rundhaug; Xiangrui Wang
Journal:  Anesth Analg       Date:  2011-03-17       Impact factor: 5.108

Review 4.  [Src protein tyrosine kinase family and acute lung injury].

Authors:  Daisuke Okutani
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2006-10

5.  Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.

Authors:  Andreas Lingel; Thomas M Weiss; Marc Niebuhr; Borlan Pan; Brent A Appleton; Christian Wiesmann; J Fernando Bazan; Wayne J Fairbrother
Journal:  Structure       Date:  2009-10-14       Impact factor: 5.006

Review 6.  Acute lung injury and the acute respiratory distress syndrome: a clinical review.

Authors:  Arthur P Wheeler; Gordon R Bernard
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

7.  p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury.

Authors:  Gang Liu; Young-Jun Park; Yuko Tsuruta; Emmanuel Lorne; Edward Abraham
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 8.  Interleukin (IL)-33: new therapeutic target for atopic diseases.

Authors:  Takeshi Nabe
Journal:  J Pharmacol Sci       Date:  2014-09-10       Impact factor: 3.337

9.  TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia.

Authors:  Ping Gong; Daniel J Angelini; Shiqi Yang; Guanjun Xia; Alan S Cross; Dean Mann; Douglas D Bannerman; Stefanie N Vogel; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

10.  IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex.

Authors:  Quentin Espinassous; Elvira Garcia-de-Paco; Ignacio Garcia-Verdugo; Monique Synguelakis; Sonja von Aulock; Jean-Michel Sallenave; Andrew N J McKenzie; Jean Kanellopoulos
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

View more
  1 in total

1.  Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury.

Authors:  Yafeng Liang; Nengli Yang; Guoquan Pan; Bingxin Jin; Shufen Wang; Wei Ji
Journal:  Cell Mol Biol Lett       Date:  2018-10-31       Impact factor: 5.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.